肿瘤微环境影响肿瘤细胞线粒体的结构和代谢功能。这个过程涉及代谢活动的变化、肿瘤细胞中活性氧（ROS）数量与正常细胞相比的增加、更多细胞内自由基的产生以及氧化途径的激活。从实用角度来看，开发靶向线粒体的药物来治疗恶性肿瘤是有利的。此类药物可以增强对特定细胞群的治疗选择性，最大限度地减少对正常组织的毒性作用，并改善联合治疗。线粒体靶向药物通常依赖于小分子药物（如合成小分子药物、植物活性成分、线粒体抑制剂或自噬抑制剂等）、修饰的线粒体递送系统药物（如亲脂性阳离子修饰或结合其他分子形成靶向药物）。线粒体剂）和一些线粒体复合物抑制剂。本文将从三个主要领域回顾这些化合物：氧化磷酸化 (OXPHOS)、ROS 水平的变化以及内源性氧化和凋亡过程。版权所有 © 2023 Yang、An、Ren、Wang、Bai、Du 和 Kong。

The tumor microenvironment affects the structure and metabolic function of mitochondria in tumor cells. This process involves changes in metabolic activity, an increase in the amount of reactive oxygen species (ROS) in tumor cells compared to normal cells, the production of more intracellular free radicals, and the activation of oxidative pathways. From a practical perspective, it is advantageous to develop drugs that target mitochondria for the treatment of malignant tumors. Such drugs can enhance the selectivity of treatments for specific cell groups, minimize toxic effects on normal tissues, and improve combinational treatments. Mitochondrial targeting agents typically rely on small molecule medications (such as synthetic small molecules agents, active ingredients of plants, mitochondrial inhibitors or autophagy inhibitors, and others), modified mitochondrial delivery system agents (such as lipophilic cation modification or combining other molecules to form targeted mitochondrial agents), and a few mitochondrial complex inhibitors. This article will review these compounds in three main areas: oxidative phosphorylation (OXPHOS), changes in ROS levels, and endogenous oxidative and apoptotic processes.Copyright © 2023 Yang, An, Ren, Wang, Bai, Du and Kong.